ストックスクリーナーアプリを入手
7.715
3.92%
-0.315
アフターアワーズ：
7.40
-0.315
-4.08%
前日終値:
$8.03
開ける：
$7.87
24時間の取引高:
1.84M
Relative Volume:
1.29
時価総額：
$687.72M
収益：
$380.79M
当期純損益:
$49.27M
株価収益率:
11.02
EPS:
0.7
ネットキャッシュフロー:
$10.68M
1週間 パフォーマンス:
-5.34%
1か月 パフォーマンス:
+20.36%
6か月 パフォーマンス:
+111.37%
1年 パフォーマンス:
+272.71%
1日の値動き範囲:
$7.685
$8.08
1週間の範囲:
$7.685
$8.29
52週間の値動き範囲:
$1.76
$8.72
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
名前
Amylyx Pharmaceuticals Inc
セクター
電話
617-683-0917
住所
43 THORNDIKE STREET, CAMBRIDGE
AMLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
7.715 | 715.80M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Guggenheim | Buy |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-05-30 | 開始されました | TD Cowen | Buy |
| 2025-04-07 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-11-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-03-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-11 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-24 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-01-05 | 開始されました | BofA Securities | Buy |
| 2022-05-25 | 開始されました | Citigroup | Buy |
| 2022-04-01 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース
What is the risk reward ratio of investing in Amylyx Pharmaceuticals Inc. stockChart Pattern Updates For Fast Growth - jammulinksnews.com
What are the latest earnings results for Amylyx Pharmaceuticals Inc.Stock Strategy Review That Work - jammulinksnews.com
How volatile is Amylyx Pharmaceuticals Inc. stock compared to the marketExpert Picks Outlook From AI Tools - jammulinksnews.com
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace
Amylyx Pharmaceuticals Announces Q2 2025 Earnings Call: Here's How to Join the Discussion - Stock Titan
What is the dividend policy of Amylyx Pharmaceuticals Inc. stockEarnings Report Alerts For Every Investor - jammulinksnews.com
What institutional investors are buying Amylyx Pharmaceuticals Inc. stockSwing Trade Report To Watch Now - jammulinksnews.com
Can trapped investors hope for a rebound in Amylyx Pharmaceuticals Inc.Step-by-Step Trade Signal Implementation Guide Ready - metal.it
Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114 - MSN
Elliott Wave Theory Predicts Pullback in Amylyx Pharmaceuticals Inc.Weekly Stock Watch With Growth Focus Expanded - metal.it
How Amylyx Pharmaceuticals Inc. stock reacts to Fed policy changesSafe Entry Stock Watch Suggestions for Cautious Traders - metal.it
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attentionSector Rotation Based Trading Opportunities Identified - metal.it
What are analysts’ price targets for Amylyx Pharmaceuticals Inc. in the next 12 monthsStrong return on investment - jammulinksnews.com
Is it the right time to buy Amylyx Pharmaceuticals Inc. stockTrack top-performing stocks in real-time - jammulinksnews.com
What are the technical indicators suggesting about Amylyx Pharmaceuticals Inc.Get exclusive market insights for better trading - jammulinksnews.com
Is Amylyx Pharmaceuticals Inc. a growth stock or a value stockAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
How many analysts rate Amylyx Pharmaceuticals Inc. as a “Buy”Maximize returns with smart investment plans - jammulinksnews.com
How Amylyx Pharmaceuticals Inc. stock performs during market volatilityFree Access to Community with 300% Return - metal.it
What catalysts could drive Amylyx Pharmaceuticals Inc. stock higher in 2025Unlock real-time stock alerts for quick profits - jammulinksnews.com
What are Amylyx Pharmaceuticals Inc. company’s key revenue driversExponential return rates - jammulinksnews.com
UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
What makes Amylyx Pharmaceuticals Inc. stock price move sharplyAchieve consistent profits with disciplined trading - jammulinksnews.com
Amylyx Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Selection - PrintWeekIndia
Is Amylyx Pharmaceuticals Inc. a good long term investmentConsistent high-yield stocks - PrintWeekIndia
What analysts say about Amylyx Pharmaceuticals Inc. stockConsistently superior profits - PrintWeekIndia
Hypoglycemia Clinical, Companies, Therapeutic Assessment, - openPR.com
What drives Amylyx Pharmaceuticals Inc. stock priceHigh-return market picks - jammulinksnews.com
Published on: 2025-07-22 15:57:30 - jammulinksnews.com
autocarpro> 2025> What drives Amylyx Pharmaceuticals Inc. stock priceRobust financial gains - Autocar Professional
Amylyx Pharmaceuticals: High-Risk, High-Reward Biotech Play with Game-Changing Pipeline Catalysts in 2026 - AInvest
Amylyx Pharmaceuticals Inc (AMLX) 財務データ
収益
当期純利益
現金流量
EPS
Amylyx Pharmaceuticals Inc (AMLX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bedrosian Camille L | Chief Medical Officer |
Mar 31 '25 |
Sale |
3.47 |
12,425 |
43,082 |
194,375 |
| Mazzariello Gina | Chief Legal Officer |
Mar 31 '25 |
Sale |
3.48 |
9,192 |
31,954 |
187,969 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 31 '25 |
Sale |
3.47 |
21,490 |
74,482 |
3,355,280 |
| Klee Justin B. | Co-Chief Executive Officer |
Mar 31 '25 |
Sale |
3.46 |
21,490 |
74,454 |
3,355,276 |
| Zeiher Bernhardt G | Director |
Mar 20 '25 |
Buy |
3.70 |
10,000 |
37,005 |
10,000 |
| Klee Justin B. | Co-Chief Executive Officer |
Mar 03 '25 |
Sale |
3.15 |
4,595 |
14,483 |
3,196,648 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 03 '25 |
Sale |
3.17 |
4,595 |
14,549 |
3,196,652 |
| Mazzariello Gina | Chief Legal Officer |
Mar 03 '25 |
Sale |
3.12 |
1,611 |
5,022 |
133,310 |
| Mazzariello Gina | Chief Legal Officer |
Feb 24 '25 |
Sale |
3.15 |
4,169 |
13,145 |
134,921 |
| Klee Justin B. | Co-Chief Executive Officer |
Feb 05 '25 |
Option Exercise |
1.57 |
36,310 |
57,007 |
3,201,243 |
0.93%
0.15%
大文字化:
|
ボリューム (24 時間):